focus -WSS

focus

author：fashion 2025-09-29 23:28:11 - browse：87342

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

knowledge

WSS

The pink breast cancer awareness ribbon needs a redesign

WHO may add ‘noma' to its list of neglected tropical diseases

Paying for Covid pills will soon shift to insurers

Physician subsidies by hospitals soar in wake of No Surprises Act

Biotech stock slump in 2023: awaiting the turnaround

The pink breast cancer awareness ribbon needs a redesign

focus

focus

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Changes to biosimilar regulatory framework must prioritize patients

Alkermes shareholders re

Testing for cancer recurrence creates a new limbo for patients

The high cost of giving birth even with insurance

Senate panel to vote on hospitals, PBMs, prisoner care

Alkermes shareholders re

WHO may add ‘noma' to its list of neglected tropical diseases

Psychedelics group wrestles with new pharma identity

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Wikipedia

EpiPen alternative approval delay highlights citizen petition issue

The pink breast cancer awareness ribbon needs a redesign

Eli Lilly to pay $200M for Beam’s stake in gene

Readout LOUD podcast: possible new ALS drug, artificial wombs

Cassava reveals details — and problems — with Alzheimer's study

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Wikipedia

hotspot

knowledge

entertainment